RxDoctor Payments Data

Brian Weber, PA

Physician Assistant · Commerce, TXNPI 1255313763

Payments from drug & device makers

$4,819in general payments, 2019–2025

Across 297 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$833
  • GSK$794
  • AstraZeneca$516
  • Teva Pharmaceuticals USA, Inc.$430
  • Bayer$235
  • Lilly USA, LLC$232
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$4,819100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,819 in reported general payments places this provider in the 85th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$1,428
Medicare patients
46
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$90,197
OzempicSemaglutide61$74,289
EliquisApixaban77$73,166
MounjaroTirzepatide44$62,749
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$59,345
JanuviaSitagliptin Phosphate30$44,251
FarxigaDapagliflozin Propanediol27$37,601
VraylarCariprazine Hcl20$32,343
LinzessLinaclotide31$28,077
TrulicityDulaglutide21$28,016
EntrestoSacubitril/Valsartan32$27,004
XareltoRivaroxaban33$26,213
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$23,021
Soliqua 100-33Insulin Glargine/Lixisenatide26$22,953
Synjardy XrEmpagliflozin/Metformin Hcl16$22,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$20$112,29683 claims
Lilly USA, LLCMounjaro, Trulicity$232$90,76565 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$794$90,428108 claims
Novo NordiskOzempic$112$74,28961 claims
PfizerEliquis$191$73,16677 claims
AbbVieVraylar, Linzess$833$60,42151 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$516$57,18361 claims
NovartisEntresto$19$27,00432 claims
Johnson & JohnsonXarelto$58$26,21333 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$13$25,74656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Commerce

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →